GALDERMA
Cetaphil®, a leading dermatologist-recommended sensitive skincare brand, is launching a first-of-its-kind global skincare immersion. This immersion will put the sensitive skin science behind its formulas to the ‘ultimate skin stress test’ at New York Fashion Week (NYFW).
As an extension of the brand’s ‘We Do Skin, You Do You’ campaign, Cetaphil’s NYFW activation will enlist influencers and consumers from 14 different countries to be the ‘Face of Cetaphil.’ They will have entered a global contest to win a trip to New York City, where they will act as on-the-ground correspondents alongside other influencers. The delegates will participate in 48 hours of Fashion Week events and activations putting Cetaphil’s sensitive skincare formulas to the test.
“In 2022, we debuted the global ‘We Do Skin. You Do You’ campaign to help empower those with sensitive skin to do more of the things they love – without hesitation. This year, with the ‘Face of Cetaphil,’ we are bringing the campaign to life by tapping into a cultural moment that is very relevant to our consumers. New York Fashion Week is the perfect place to put the brand at the forefront of where fashion, beauty and skincare intersect.”
GERRY MUHLE
|
|
The initiative includes partnerships with contemporary fashion brand Alice + Olivia, modeling and talent agency Wilhelmina International Inc. and global fashion and media brand, Highsnobiety. The competition winners will be joined by sensitive skin expert Dr. Lindsey Zubritsky, board-certified dermatologist at Premier Dermatology and Skin Cancer Center in Ocean Springs, Mississippi, U.S.
“Some cosmetics are a main trigger of sensitive skin, due to the inclusion of potentially irritating ingredients and regular usage. Similarly for clothing, when fabrics interact with skin that has an interrupted skin barrier, products can lead to irritated skin or skin conditions such as contact dermatitis. Scientific research is foundational to everything Cetaphil does, and research has shown that sensitive skin needs extra care. Cetaphil products can help restore and rebuild the skin moisture barrier, helping to reduce skin aggravation. This ultimately helps people feel comfortable in their own skin – and in their beauty and fashion looks.”
DR. LINDSEY ZUBRITSKY
|
|
As Alice + Olivia’s exclusive skincare sponsor, Cetaphil will have a strong presence backstage at one of Fashion Week’s hottest shows. The partnership will include a ‘skincare prep’ area where models will have the opportunity to meet with a Cetaphil skin expert and have their skin prepped using Cetaphil products. These include the Gentle Skin Cleanser, Healthy Renew Face Serum and Moisturizing Lotion, which ensure a hydrated canvas for makeup and clothing application.
“Over many NYFW seasons, I’ve learned how important a great skincare routine is to make up for the long hours and lack of sleep that go into making our beautiful shows a reality. We’re so excited to partner with Cetaphil this season as our skincare sponsor. Glowing skin is the ultimate accessory, and their products work magic to protect and hydrate.”
STACEY BENDET
|
|
Through Cetaphil’s partnership with Wilhelmina Modeling Agency, attendees will also get exclusive access to a group of models who are walking in NYFW shows. These experiential, behind-the-scenes moments will give them an insider’s look at Fashion Week, seeing how it impacts skin, through the eyes of a model.
A Cetaphil x Highsnobiety pop-up will take place on Saturday, February 10 from 11:00 AM to 6:00 PM. The space will serve as a fashion-forward sensitive skin sanctuary where New Yorkers can relax and refuel amidst the hustle and bustle of Fashion Week. The pop-up will be completed with skin consultations, beauty services, custom hydrating beverages and more.
To follow the Face of Cetaphil throughout NYFW, check out your country’s Cetaphil handles on Instagram and TikTok. The brand will be sharing content across its channels.
About Cetaphil
Seventy-five years ago, a leading pharmacist created the first Cetaphil product – a gentle, yet powerful formula to clean without stripping and moisturize without clogging. Today, Cetaphil is dermatologist-recommended for sensitive skin and recognized around the world. With the help of leading skincare experts, Cetaphil continues to develop innovative skincare technologies for sensitive skin that help restore, protect and maintain skin’s health every day. For more information, visit www.cetaphil.com.
About Galderma
Galderma is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market though Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240207631228/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Pilots to Profit: NTT DATA's 2026 Global AI Report Shows How Top Performers Turn AI Vision Into Value8.12.2025 14:00:00 CET | Press release
Study reveals how the top 15% of companies are 2.5x more likely to post >10% revenue growth and over 3x more likely to achieve ≥15% profit margins from AI deployments NTT DATA, a global leader in AI, digital business and IT services, today released the 2026 Global AI Report: A playbook for AI leaders. The playbook is based on the company’s new benchmark research and reveals how “AI leaders” are separating from competitors through strategy and execution. The analysis is based on a survey of 2,567 senior executives across 35 countries and 15 industries. Only 15% of participating organizations qualified as “AI leaders,” defined by clear AI strategies, mature operating models and focused execution. These leaders report significantly higher revenue growth and profit margins than other organizations. “AI accountability now belongs in the boardroom and demands an enterprise-wide agenda,” said Yutaka Sasaki, President and CEO, NTT DATA Group. “Our research shows that a small group of AI leader
AdvanCell Receives First Delivery of High-Activity Thorium-228, Highlighting a Unique Industry Capability and Expertise Essential to Scaling Lead-212 Production for Targeted Alpha Therapies8.12.2025 14:00:00 CET | Press release
Thorium-228 (228Th) is the parent isotope and key starting material to produce the alpha-emitter Lead-212 (212Pb) The established capability to receive and process high-activity 228Th, provides a key competitive advantage in scaling up 212Pb production to support the rapid advancement of 212Pb-ADVC001 (ADVC001) clinical development and the expanding pipeline The received 228Th will be processed into sources for our proprietary generator and installed in production systems first in Australia and subsequently in the US, as part of the planned expansion AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced it has received the first delivery of high-activity 228Th, the parent isotope of 212Pb and a key starting material to produce the alpha-emitter 212Pb, used to manufacture ADVC001, the company’s lead asset, and other 212Pb-based radioligand therapies in the pipeline. This delivery marks a major milestone for the
BRUKINSA Delivers Landmark 74% 6-Year PFS in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia8.12.2025 14:00:00 CET | Press release
Multiple long-term follow-up studies confirm BRUKINSA’s superior efficacy and favorable tolerability versus ibrutinib in relapsed or refractory CLLAdditional ASH data from investigational BTK degrader, BGB-16673, highlight potential first- and best-in-class activity with durable responses in heavily pretreated patients with CLL BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) innovation by showcasing the depth, quality, and momentum of its hematology portfolio at the 67th ASH Annual Meeting and Exposition in Orlando, Florida. The totality of BeOne’s ASH data reinforce BRUKINSA® (zanubrutinib) as the foundational Bruton’s tyrosine kinase inhibitor (BTKi) of choice. “At ASH 2025, we will present new data from across our CLL franchise, highlighting both the strength of BRUKINSA and the potential of BGB-16673,” said Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology,
Pink Changing Lives®: Mary Kay Builds 11th Preschool in Sri Lanka, Turning a Dream Into Thousands of New Beginnings8.12.2025 14:00:00 CET | Press release
Each year, Mary Kay supports causes that enrich millions of women’s lives globally, including access to education Mary Kay Inc., a global champion for women’s empowerment, is turning pink into purpose through its Pink Changing Lives® Program to raise awareness and funds to support life-changing programs advancing cancer research, support survivors of domestic violence, protect our planet’s most precious resources, and create opportunities that help women and their families thrive. Since 1996, the multi-faceted Pink Changing Lives® Program has donated over $230 million in monetary and in-kind donations to improve the lives of women and their families in communities around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208554750/en/ Mary Kay Inc., a global champion for women’s empowerment, is turning pink into purpose through its Pink Changing Lives® Program to raise awareness and funds to support life-changing p
IonQ Expands in EU With Slovakia’s First National Quantum Communication Network8.12.2025 13:05:00 CET | Press release
Partnering with the Slovak Academy of Sciences, IonQ bolsters national security and European quantum communications infrastructure IonQ (NYSE: IONQ), the world’s leading quantum company, through its subsidiary ID Quantique (IDQ), today announced the deployment of Slovakia’s first national quantum communication network. Developed in partnership with the Institute of Physics, Slovak Academy of Sciences (IPSAS), the new system features a resilient hybrid architecture designed to strengthen the country’s cybersecurity infrastructure and support Europe’s quantum digital programs. The Slovak Quantum Communication Infrastructure (skQCI) project represents a major milestone in Slovakia’s contribution to the European Quantum Communication Infrastructure (EuroQCI) initiative, which seeks to establish a secure quantum-resistant communication backbone covering all European Union (EU) member states and territories. By integrating quantum-safe technologies at a national scale, Slovakia will directly
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom